What is Liminatus Pharma, Inc. Class A Common Stock (LIMN) stock price today?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) currently trades at $0.20 per share. The stock has a market capitalization of $9.09M and a P/E ratio of —x.

Is LIMN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Liminatus Pharma, Inc. Class A Common Stock has a Smart Value Score of 17/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -23.66.

Is Liminatus Pharma, Inc. Class A Common Stock financially healthy?

Liminatus Pharma, Inc. Class A Common Stock's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -23.66 places it in the distress.

LIMN

Liminatus Pharma, Inc. Class A Common Stock

NASDAQ: LIMN · HEALTHCARE · BIOTECHNOLOGY

$0.20

-0.15% today

Updated 2026-04-30

Market cap

$9.09M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.43

Dividend yield

—

52W range

$0 – $34

Volume

5.0M

Market cap

$9.09M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.43

Dividend yield

—

52W range

$0 – $34

Volume

5.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

4.5

Quality

3.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-23.7

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$—

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity -0.88x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -23.66 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-386847.00

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-2.93M	$-1.23M	$-2.90M	$-10.21M	$-8.17M
EPS	—	—	—	—	$-0.43
Free cash flow	$-869000.00	$-3.35M	$-3.11M	$-9.98M	$-386847.00
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LIMN	$9.09M	17	4.3	3.5	5.0	4.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Liminatus Pharma, Inc. Class A Common Stock trades at $0.20. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -23.66, it sits in the distress.

Frequently asked questions

What is Liminatus Pharma, Inc. Class A Common Stock's stock price?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) trades at $0.20.

Is Liminatus Pharma, Inc. Class A Common Stock overvalued?

Smart Value Score 17/100 (Grade F, Strong Sell).

What is the price target of Liminatus Pharma, Inc. Class A Common Stock (LIMN)?

The analyst target price is $—, representing NaN% downside from the current price of $0.20.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-23.66 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

liminatuspharma.com

Quick metrics

P/S ratio—

ROE—

Beta0.63

50D MA$0.22

200D MA$1.65

Shares out0.04B

Float0.03B

Short ratio—

Avg volume5.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

LIMN vs LLY →LIMN vs JNJ →LIMN vs ABBV →Stock screener →